Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial tests the safety, side effects, and best dose of azenosertib in combination with trastuzumab deruxtecan in treating patients with HER2-positive gastric or gastroesophageal junction cancer and other HER2-positive solid tumors that have spread to nearby tissue or lymph nodes (locally advanced), that have spread from where it first started (primary site) to other places in the body (metastatic), or that cannot be removed by surgery (unresectable). Azenosertib is in a class of medications called kinase inhibitors. It inhibits a protein called Wee1. Inhibition of the Wee1 protein can make tumor cells more vulnerable to chemotherapy drugs, leading to tumor cell death. Trastuzumab deruxtecan is in a class of medications called antibody-drug conjugates. It is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers deruxtecan to kill them. Giving azenosertib in combination with trastuzumab deruxtecan may be safe, tolerable, and/or more effective in treating patients with locally advanced, metastatic, or unresectable HER2-positive gastric, gastroesophageal junction, or other solid tumors, compared to just trastuzumab deruxtecan alone.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Nowotwór rozpoznany histologicznie (potwierdzony badaniem tkanki) - zaawansowany, niemożliwy do operacji lub przerzutowy
- •Komórki raka mają białko HER2 (wykazane w badaniu patologicznym)
- •Pacjent wcześniej nie otrzymywał leczenia lekiem DS-8201a (trastuzumab derukstekan)
- •Wcześniejsze leczenie co najmniej jednym innym schematem dla zaawansowanego nowotworu
- •Wiek co najmniej 18 lat
- •Dobry stan ogólny pacjenta (zdolność do codziennych aktywności na poziomie nie gorszym niż 70%)
- •Wystarczająca liczba białych krwinek (wynik laboratoryjny z ostatnich 7 dni)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 4, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
UT MD Anderson Cancer Center
Houston, United States
Trial contact
Site Public Contact
Funda Meric-Bernstam
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/28/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.